News about "Biosimilars "

Viatris to Receive USD 400 Million in Cash and USD 415 Million in Equity Shares of Biocon

Viatris is set to receive USD 400 million in cash and USD 415 million in Biocon equity shares as part of a revised agreement, accelerating the end of non-compete restrictions in the biosimilars space and enabling both companies to pursue expanded market opportunities.

Biosimilars | 08/12/2025 | By Dineshwori

Indian Pharmaceutical Alliance Welcomes New Leadership

Dr. Sharvil Patel, Managing Director, Zydus Lifesciences, and Vice President, Indian Pharmaceutical Alliance (IPA), has been appointed President of the alliance, while Glenn Saldanha, Chairman and Managing Director, Glenmark, will serve as the new Vice President.

Biosimilars | 04/10/2025 | By Dineshwori |  139

India's Pharma 2.0: Moving Beyond Generics to Innovation

For decades, India has been known as the “pharmacy of the world.” The country built this reputation on its strength in generics. Low-cost medicines from Indian companies reached millions across the globe. They helped make treatments affordable in developed and developing nations alike.

Biosimilars | 13/09/2025 | By Darshana |  251

Sandoz Reports Strong H1 2025 Results, Accelerated Growth in Biosimilars and Generics

Sandoz has reported strong financial results for the first half of the financial year 2025, with the company’s net sales reaching USD 5.2 billion. Growth accelerated in the second quarter, driven by solid performance across both the generics and biosimilars businesses.

Biosimilars | 07/08/2025 | By Dineshwori |  403

Sandoz to Acquire Just-Evotec Biologics in USD 300 Million Deal

Sandoz has signed a non-binding term sheet with Evotec SE, paving the way for the potential acquisition of Just–Evotec Biologics EU SAS for approximately USD 300 million.

Biosimilars | 30/07/2025 | By Dineshwori |  234

Samsung Bioepis Partners with Harrow for US Commercialisation of Ophthalmology Biosimilars

Following the transition of commercial rights from Biogen back to Samsung Bioepis, Harrow will assume full responsibility for the commercialisation of both BYOOVIZ and OPUVIZ biosimilars in the US.

Biosimilars | 18/07/2025 | By Dineshwori |  154

Sandoz Begins Construction Of USD 440 Million Biosimilars Production Facility In Slovenia

Sandoz is constructing a new facility in Slovenia to strengthen its European biosimilar hub and expand its global market presence.

Biosimilars | 10/07/2025 | By Dineshwori |  378

Global API Market Expected to Reach USD 422.8 Billion by 2034

The global Active Pharmaceutical Ingredients (API) market is projected to grow at a compound annual growth rate (CAGR) of 6.7 percent to an estimated USD 422.8 billion by 2034, according to a report.

Biosimilars | 09/07/2025 | By Dineshwori |  156

Lupin Signs USD 50 million Deal with Zentiva to Commercialise Biosimilar Certolizumab Pegol Globally

Zentiva will be responsible for marketing and distribution of Lupin’s biosimilar Certolizumab Pegol outside the USA and Canada—primarily across Europe and the CIS (Commonwealth of Independent States) region.

Biosimilars | 09/07/2025 | By Dineshwori |  252

Bio-Thera Solutions, Tabuk Pharmaceutical Partner to Commercialise BAT2206 in Saudi Arabia

Bio-Thera Solutions Inc. has partnered with Tabuk Pharmaceutical Manufacturing Company, a fully-owned subsidiary of Astra Industrial Group, for BAT2206, its ustekinumab biosimilar.

Biosimilars | 26/12/2024 | By Abha |  735